This Article is in Formatting stage. Final pdf will get change

Journal: Research & Reviews: Journal of Computational Biology
ISSN: 2319-3433

Title: IN SILICO ANALYSIS AND DOCKING STUDY OF THE ACTIVE PHYTO COMPOUNDS OF BACOPA MONNIERI AGAINST ALZHEIMER DISEASE

Research Article

Volume:13
Issue:02
Year:2024

Article Received: 9 May 2024
Article Accepted: 8 Oct 2024
Article Published:

Anushka Sahu

Student,School of biotechnology, Devi Ahilya Vishwavidyalaya, University in indore, India.
Email: anushkasahu.1403@gmail.com

Abstract

Objective: Alzheimer is a neurodegenerative disease and is the cause of 60–70% of cases of dementia. It infected a million people worldwide. An effort was undertaken to explore the potential of natural compounds found in *Bacopa monnieri*, a plant renowned for its extensive medicinal properties in Indian Ayurveda, to combat the disease. This was achieved through molecular docking studies, evaluation of drug-likeness, and comprehensive ADME (absorption, distribution, metabolism, and excretion) analysis, along with toxicity predictions.

Methods: The primary β-secretase protein was obtained from the PDB database. Ligands with weak binding affinity and molecules that could interfere with the docking process were excluded. Docking was then performed using the PyRx tool. The pharmacokinetic properties, including absorption, distribution, metabolism, and excretion (ADME), as well as the drug-likeness of the compounds, were assessed utilizing the Swiss-ADME and ChemAGG platforms.

Results: Ramachandran plot analysis illustrates the statistical distribution of the backbone dihedral angles ϕ (phi) and ψ (psi), providing insights into the conformational preferences of the protein structure.

Molecular docking studies identified that only one compound from *Bacopa monnieri* exhibits significant binding affinity, potentially inhibiting the β-secretase enzyme by preventing plaque formation. The ADMET analysis, along with drug-likeness and toxicity predictions, confirmed that ascorbic acid is both safe and possesses favorable drug-like characteristics.

Conclusion: This study indicates that ascorbic acid demonstrates a specific binding affinity, with the potential to inhibit the β-secretase enzyme. This suggests its potential role in therapeutic strategies for managing Alzheimer's disease.

Keywords: Alzheimer disease (AD), β-secretase (BACE), Baccopa monnieri (BM), Docking, 4ACU, amyloid

This Article is in Formatting stage. Final pdf will get change

INTRODUCTION

German Psychiatrist Alois Alzheimer was the first to study and identify Alzheimer's disease (AD) as the primary cause of senile dementia in 1906. It cannot be diagnosed with certainty while an individual is alive and has, up to now, been associated with an unclear or complex aetiology [1]. Alzheimer's disease (AD) is a neurodegenerative disorder that advances progressively and has no known cure.. It is characterised by cognitive and functional deficiencies, loss of functional independence, and behavioural changes. Deficits in short-term memory, praxis, visuospatial impairment, and executive dysfunction are the primary cognitive signs of AD [2] .The impact of AD on patients, caregivers, and healthcare systems is enormous. The precise cause of AD is still unknown despite decades of research; it is thought to involve a number of genetic, environmental, and molecular variables [3]. In 2020, the global number of dementia patients was approximately 55 million. This figure is projected to reach 78 million by 2030 and is expected to nearly double by 2050, rising to 139 million. [4].

A key protein involved in the development of Alzheimer's disease (AD) is beta-secretase, also known as beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) [5]. The production of the amyloid-beta peptide (Aβ), a crucial factor in the advancement of the illness, is facilitated by its multifarious involvement in AD [6]. The Golgi apparatus and endoplasmic reticulum of neurons are the primary locations for the aspartyl protease enzyme BACE1. It cleaves the amyloid precursor protein (APP) at the beta-secretase site, which is the main way it helps AD by starting the peptide formation of Aβ [7]. Neurotoxic oligomers and amyloid plaques are the end result of the accumulation of Aβ peptides, especially the more, hydrophobic and longer Aβ42 form [8]. These plaques causes neuroinflammations impair
neuronal function, and are linked to cell death and malfunction in synapses. BACE1's connection to the initial phases of Aβ synthesis highlights its function in AD [9]. While overexpression or overactivity of BACE1 is often detected in sporadic AD, which accounts for most cases, overproduction of Aβ is caused by mutations in either the presenilin or APP genes in familial AD cases [10]. Consequently, a primary objective in the development of Alzheimer's disease (AD) treatments has been to inhibit the activity of BACE1.It is believed that decreasing Aβ generation will slow or perhaps stop the disease from progressing [11]. It is crucial to remember that BACE1 has substrates besides APP, and therefore totally inhibiting BACE1 could have unexpected effects [12]. Furthermore, the link between Aβ and AD is complicated, and the disease is also greatly influenced by other variables such inflammation and tau pathology [13].
The medical system known as Ayurveda originated in India and has persisted as a separate entity from distant antiquity to the present [14]. The Ayurvedic tradition emerged and evolved in India between 2500 and 500 BC. Often referred to as the "science of longevity," Ayurveda provides a comprehensive framework for promoting a long and healthy life. [15]. Ayurveda provides programs designed to rejuvenate the body through proper diet and nutrition. It also offers therapeutic approaches to address various common ailments, including food allergies, for which there are limited modern treatment options. [16].

Bacopa monnieri (BM) has been utilized by Ayurvedic practitioners in India for nearly 3000 years and is categorized as a medhyarasayana, a type of herbal remedy that enhances memory and cognitive function (medhya). [17]. The earliest documented reference to *Bacopa monnieri* (BM) can be found in various ancient Ayurvedic texts, such as the *Caraka Samhita* (6th century A.D.), where it is recommended in formulations for addressing a variety of mental health issues, including anxiety, impaired cognition, and lack of concentration. Additionally, it is mentioned in the *Bravprakash Var-Prakarana* (16th century A.D.).the *Bravprakash Var-Prakarana* (16th century A.D.) Brahmi, or Bacopa monnieri (Linn.) Pennell (Scrophulariaceae), is a well-known Ayurvedic herb that is said to enhance memory and cognition. B. monnieri may be able to enhance cognition, according to a meta-analysis of randomised controlled trials on the extract's effects on cognition [18].

It also has demonstrated significant pharmacological properties such as gastrointestinal discomfort, rejuvenation, promoting memory and intellect, skin disorders, epilepsy, pyrexia and analgesia, antiepileptic, anxiolytic, depressive, sedative, antioxidant, and anti-inflammatory properties [19]. It was discovered that the standardised extract of Bacopa enhanced with bacosides functionally activated the synaptic proteins. Neurological conditions such Alzheimer's disease, anterograde/retrograde amnesia, memory loss

This Article is in Formatting stage. Final pdf will get change

brought on by okadaic acid, aluminium chloride, a specific protein phosphatase inhibitor, oxidant damage, and signs of autism brought on by sodium valproate, a feeble sodium ion [20]. Bacopa therapy has been demonstrated to enhance channels and GABA transaminase inhibitor [21]. The decrease of cholinergic neuronal activity in the hippocampus is the main characteristic of Alzheimer's disease [22]. It has been discovered that BM reduces the acetylcholinesterase (AChE) activity throughout the brain, which may possibly indicate that BM is a useful memory-restoring medication in the treatment of Alzheimer's and other related dementias [23]. In this study, an attempt was made to identify new active and stable inhibitors of beta secretase protein 4ACU from a total of 34 different active phytocompounds of the Bacopa monnieri plant.

Material and methods

Protein preparation

The three-dimensional crystal structure of the β-secretase [BACE-1] protein (Protein data bank (PDB) ID: 4ACU) was retrieved from the (Research Collaboratory for Structural Bioinformatics) PDB (https://www.rcsb.org/) [24]. (Fig. 2) It has a single chain A consisting total of 411 amino acids. It has a crystal resolution of 1.75 Å. Prior to docking, protein crystal structures are prepared to optimise hydrogen bonding and eliminate atomic collisions. Using the Discovery Studio Visualizer 21.1 standard protocol, protein preparation was carried out. After removing the water molecules and heteroatoms from the proteins, polar hydrogen was introduced.. Moreover, the prepared protein's active site was predicted.

Ramachandran plot

A plot of a peptide's torsional angles, phi and psi, is called a Ramachandran plot. Utilizing the web-based PDB sum service of EMBL-EBI (https://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=4acu&template=procheck_summary.html) [25], a Ramachandran plot analysis was conducted . After submitting the PDB ID for Protein (4ACU), a Ramachandran plot analysis was performed, labelling outliers according to the type, number, and chain of residues and showing all of the labels.

Ligand Selection

A total of 36 active phytocompounds from Bacopa monnieri were extracted in order to document possible BACE-1 inhibitors. The 3D SDF (Three-Dimensional Structure Data File) format was used to retrieve phytocompound structures from the PubChem chemical database (https://pubchem.ncbi.nlm.nih.gov/) [26] . The PyRx tool was used to optimise the ligand, minimise its energy, and convert it to 3D PDB format in order to prepare it for use.

Molecular Docking

The molecular docking method simulates the atomic-level interaction between a tiny molecule and a protein, allowing us to better understand fundamental biochemical processes and define the behaviour of small molecules in the binding sites of target proteins. The molecular docking investigation employed PyRx, a virtual screening tool software . All 36 active phytocompounds of B. monnieri were docked with BACE-1 using the PyRx programme (PDB ID: 4ACU). Targets for the docking investigation were specified using prepared receptors and ligand files. Using the tool's open-babel tab, ligands were imported and produced once the protein was loaded and transformed into a macromolecule for docking [27]. The grid box was defined by maximising to examine all possibility for

ligand to bind with protein after the protein and ligand molecules were identified. Docking was initiated by clicking the forward button after everything had been adjusted. Following docking, we were given a table with each ligand's binding affinity. Top 5 ligands were selected for further study based on the highest binding affinity

This Article is in Formatting stage. Final pdf will get change

of the ligand, but they are not passing ADME analysis. Next top 5 compounds are selected and were saved in PDB file format. Discovery studio visualizer 21.1 was used to conduct an interactive two-dimensional (2D) three-dimensional (2D) visualisation investigation.

Analysis of Absorption, Distribution, Metabolism, and Excretion (ADME)

SwissADME (http://www.swissadme.ch/) was employed to evaluate pharmacokinetic parameters of the ligands, focusing on absorption, distribution, metabolism, and excretion (ADME). The primary aim of this analysis is to provide insights that support drug development. These four criteria influence the compound's performance and pharmacological activity, as they play a crucial role in determining drug levels and the kinetics of drug exposure within tissues.In this research study, Top 5 compounds having highest binding affinity were taken for the drug likeness test and ADMET analysis, but they do not pass the test. Next 5 compounds were taken for drug-likeness and ADMET analysis was done using SWISS-ADME (http://www.swissadme.ch/) [26] and ProTox 2 (https://tox-new.charite.de/protox_II/). Boiled-Egg analysis was also carried out with the SWISS-ADME tool (Fig. 3). The ADME analysis took Lipinski's rule of five into account. When a molecule conforms to two or more of the five criteria listed by Lipinski, it can be predicted whether or not a drug-likeness will be successful. Conditions,

1. Molecular mass
2. Log P <4.15,
3. H-bond donor<5
4. H-bond acceptor<10
5. 40<molar refractivity<130

Results

Ramachandran plot

In the Ramachandran plot (Fig. 1), considering protein geometry as below,

Residues in most favored regions [A, B, L]	286	89.9%
Residues in additional allowed regions [a,b,l,p]	31	9.7%
Residues in generously allowed regions [~a,~b,~l,~p]	1	0.3%
Residues in disallowed regions	0	0.0%
Number of non-glycine and non-proline residues	318	00.0%
Number of end-residues (excl. Gly and Pro)		3
Number of glycine residues (shown as triangles)		33
Number of proline residues		18
Total number of residues		**372**

This Article is in Formatting stage. Final pdf will get change



Fig. 1 Ramachandran Plot analysis of 4GH9.

Molecular Docking

According to a molecular docking research, one of B. monnieri's active phytocompounds has a strong binding affinity for 4ACU. The top five phytocompounds from B. monnieri that have the most affinity for binding 4ACU (Table 1). We discovered that 10 of the 36 compounds from B.monnieri exhibit a considerable binding affinity (more than 9 Kcal/mol) with 4ACU based on the findings of molecular docking studies conducted using PyRx. The top five compounds (Table 2) were chosen based on docking results for ADME analysis and drug-likeness prediction.

Molecular visualization

Discovery Studio Visualizer 21.1 was used to visualise the interactions between the receptor and ligand of the top 5 phytocompounds with the highest binding affinity. PyRx was used to save docked ligands in PDB file format, which was subsequently opened by pure protein 4ACU. Various 2D and 3D interactions between phytocompounds and 4ACU were noted. We saw a variety of interactions on a 2D interaction diagram, including Van der Waals forces, conventional and carbon-hydrogen bonds, Pi-sulfur interactions, alkyl and Pi-alkyl interactions, Pi-Pi T-shaped interactions, and unfavourable interactions**.**

This Article is in Formatting stage. Final pdf will get change

Fig 2: 3D structure of Beta-Secretase (4ACU) protein

Heptacosane

Heptacosane forms different 2D-3D interactions with 4ACU. It include pi-sigma bond with residue LYS 107 only, carbon hydrogen bond with TYR 71 formed as shown in (fig.4).

Bacoside-A

Bacoside-A forms different 2D-3D interactions with 4ACU. It includes conventional hydrogen bond with GLY 11, THR 232 and TYR 298 ; forms Alkyl bonding with ILE 126; forms carbon-hydrogen bond with SER 35; and forms unfavourable Donor-Donor with ASN 233 formed as shown in (fig. 5).

Stigmastenol

Stigmastenol forms different 2D-3D interactions with 4ACU. It includes Conventional Hydrogen Bond with ARG 128 residues only; and forms Pi-Alkyl bond with TYR 71 as shown in (fig. 6).

.

Bacopaside-1

Bacopaside-1 forms different 2D-3D interactions with 4ACU. It includes Conventional Hydrogen Bond with ASN 233, ARG 307, GLY 11, THR 232, GLY 230, TYR 198 and ARG 128; and forms Alkyl and PI-Alkyl bond with residues TRP 76, VAL 69 as shown in (fig. 7).

Ascorbic acid

Ascorbic acid forms different 2D-3D interactions with 4ACU. It forms Conventional Hydrogen Bond with residues ARG 128, TYR 198, ASP 228, ARG 235, ASP 32 and SER 325. It also forms Carbon Hydrogen Bond with SER 35 residue. It also form Alkyl bond with LYS 321 as shown in (fig. 8).

Drug-likeness prediction, ADMET analysis, and toxicity prediction

Lipinski's rule of five helps distinguish between molecules that are drug-like and those that are not by taking into account five different factors. For the best-docked compounds, drug-likeness prediction was carried out. utilising Lipinski's rule of five, and ADME analysis was carried out with ProTox 2 server and the Swiss ADME web server. Analysis of Boiled Eggs was additionally conducted utilising ProTox and the Swiss-ADME tool (Table 2). The toxicity was calculated using two prediction servers (Table 3). Furthermore. BOILED EGG analysis was performed using the Swiss-ADME technique. watch for the blood brain barrier's passive brain access forecast (BBB) as well as intestinal absorption (HIA) and gastrointestinal absorption of some phytocompounds (Fig. 3).

Furthermore, the HIA, permeability, and water solubility (logs) of the best-docked compounds were assessed using the standard scale. Lipinski's rule, carcinogenic consequences, BBB, and glycoprotein substrate verification (Table 4)

Discussion

This Article is in Formatting stage. Final pdf will get change

In modern medicine, Alzheimer disease is treated with with anti-viral and cognitive stimulation therapies . Natural phytocompounds from medicinal plants such as Bacopa monnieri can be utilized due to its lower toxicity compared to synthetic compounds. Molecular docking, ADME analysis, and molecular dynamic simulation are examples of in silico techniques that have been demonstrated to be useful for more research to examine the ligand's stability, interactions, and binding affinity with the target. . In addition to affecting the host's immunity, BACE1 is an enzyme that cleaves the amyloid precursor protein (APP) to generate Aβ peptides, particularly the longer and more aggregation-prone forms of Aβ. In Alzheimer's disease, the accumulation of Aβ peptides can lead to the formation of toxic Aβ aggregates and the subsequent neuronal damage and cognitive decline associated with the disease. n. Hence, beta secretase can be considered as significant target. The Ramachandran plot illustrates the statistical distribution of backbone dihedral angles ϕ and ψ, representing the allowed conformations of proteins.

A current study revealed the role of phytocompounds from B. monnieri which have multiple medicinal properties according to Ayurveda. The research study indicates that one of the phytocompounds from source shows promising potential for further investigation. B. monnieri have been found effective against Alzheimer Disease. For research study, Beta secretase protein (4ACU) was analyzed for Ramachandran plot to validate the purity of the protein, and there were no outliers and poor rotamers observed. Z-Score of protein observed was –1.31 for whole residues. In order to conduct an in silico study, the molecular docking technique was utilised to verify the binding affinity of all 34 phytocompounds against the beta secretase protein (PDB ID: 4ACU). Heptacosane, Bacoside A, Ascorbic acid, Stigmastenol, and Bacopaside-1 were the five phytocompounds from B. monnieri that had the highest binding affinity after the compounds which do not follow ADME analysis. After molecular docking study, all the five compounds were further studied for ADME analysis to validate the drug likeness and toxicity. The binding of these phytochemicals with Beta secretase inhibits the production of toxic amyloid β (Aβ). Among these identified phytocompounds, Ascorbic acid can be predicted as potential inhibitors based on their significant binding affinity, drug-likeness properties, ADMET prediction, toxicity prediction (based on Predicted LD50). These phytocompounds help reduce the accumulation of amyloid plaques and counteract amyloid β toxicity. and also found safe and effective against Alzheimer disease without toxicity.



Fig 3: Boiled-Egg analysis: Ascorbic Acid

Table 1: Top 5 phytocompounds from B. Monnieri having the highest binding affinity with Beta-Secretase

S.no	PubChem Compound ID	Name of Phytocompound	Binding Energy (Kcal/mol)
1.	CID_11636	Heptacosane	-9.8
2.	CID_92043183	Bacoside-A	-9.6
3.	CID_129636603	Stigmastenol	-9.5
4.	CID_21599442	Bacopaside l	-9.4
5.	CID_54670067	Ascorbic acid	-9.5

Table 2: ADME analysis of best-docked compounds based on Lipinski's rule

S.no	Ligand name	Molecular Weight (g/mol)	H-Bond Donor	H-Bond Acceptor	Log-P	Molar Refractivity
1.	Heptacosane	380.73	0	0	7.32	131.9
2.	Bacoside-A	768.97	8	13	4.96	198.88
3.	Stigmastenol	414.71	1	1	5.13	133.64
4.	Bacopaside l	979.13	9	20	3.62	232.37
5.	Ascorbic acid	176.12	4	6	0.39	35.12

Table 3: Toxicity Prediction using ProTox-2 Server

S.No.	Ligand name	Predicted LD50 (mg/kg)	Predicted Toxicity	Avg Similarity Class	Prediction Accuracy
1.	Heptacosane	750	3	100%	100%
2.	Bacoside-A	1500	4	86.43%	70.97%
3.	Stigmastenol	5000	5	77.45%	69.26%
4.	Bacopaside l	225	3	60.29%	68.07%
5.	Ascorbic acid	3367	5	100%	100%

Table 4: ADME analysis using SwissADME

S.No.	Ligand name	LogS	HIA	Pgp-sub	BBB	Lipinski's rule

1.	Heptacosane	-9.59	Low	Yes	No	1
2.	Bacoside-A	-5.69	Low	Yes	No	3
3.	Stigmastenol	-8.78	Low	No	No	1
4.	Bacopaside l	-5.88	Low	Yes	No	3
5.	Ascorbic acid	0. 1	High	No	No	0



Fig. 4: 2D and 3D diagram of interactions of Heptacosane with Beta-secretase (4ACU) (a) 2D Structure (b) Aromatic (c) H-bonds(d) Interpolated Charges (e) Hydrophobicity (f) Ionizability (g) SAS



Fig. 5: 2D and 3D diagram of interactions of Bacoside-A with Beta-secretase (4ACU)(a) 2D Structure (b) Aromatic (c) H-bonds(d) Interpolated Charges (e) Hydrophobicity (f) Ionizability (g) SAS



Fig. 6: 2D and 3D diagram of interactions of Bacopaside-l with Beta-secretase (4ACU) (a) 2D Structure (b) Aromatic (c) H-bonds(d) Interpolated Charges (e) Hydrophobicity (f) Ionizability (g) SAS



Fig. 7: 2D and 3D diagram of interactions of Bacopaside-l with Beta-secretase (4ACU) (a) 2D Structure (b) Aromatic (c) H-bonds(d) Interpolated Charges (e) Hydrophobicity (f) Ionizability (g) SAS



Fig. 8: 2D and 3D diagram of interactions of Ascorbic Acid with Beta-secretase (4ACU)
(a) 2D Structure (b) Aromatic (c) H-bonds(d) Interpolated Charges (e) Hydrophobicity (f) Ionizability (g) SAS

Conclusion

The purpose of this study is to find B. monnieri natural plant components that may be used as Alzheimer disease treatment agents. Herpes Simplex Virus 1 (HSV-1) is a known cause, and according to reports, there were 43.8 million people worldwide suffering from dementia in 2016, marking a 117% increase from 20.3 million cases in 1990. A key target in Alzheimer's disease prevention is β-secretase (BACE), which triggers the production of amyloid-β (Aβ). Inhibiting BACE is a promising approach to combating Alzheimer's. Natural phytocompounds that target BACE can help inhibit the formation of senile plaques, thus potentially slowing the progression of the disease. this study, shows one phytocompounds from B. monnieri predicted the suppress the action of β-secretase (BACE) by preventing the formation of plaques. These phytocompounds have high potential inhibition and best binding affinity with β-secretase. The most well-studied phytocompounds with drug-like qualities, a safe ADMET profile, and efficaciousness may contribute to the development of optimal Alzheimer inhibitors and the use of Ayurvedic medicine to treat Alzheimer disease.

ACKNOWLEDGMENT

We thank BioNome to provide support in training as well as in research projects.

References

[1] Kaynara Trevisan and R. C. Pereira, "Theories of Aging and the Prevalence of Alzheimer's Disease," *BioMed Research International ,* vol. 2019, p. 9, 2019.

[2] M. Zvěřová, "Clinical aspects of Alzheimer's disease," *Science Direct,* pp. 3-6, October 2019.

[3] 1. R. K. R. a. M. A. S. Rudy J. Castellani, "Alzheimer Disease," *Dis Mon,* p. 56, 2010.

[4] "Alzheimer's Disease: Facts & Figures," BrightFocus Foundation, 5 october 2022. [Online].

[5] Prof Riqiang Yan Prof Robert Vassar, "Targeting the β secretase BACE1 for Alzheimer's disease therapy," *The Lancet Neurology,* vol. 13, no. 3, pp. 319-329, 2014.

[6] S. L. C. a. R. Vassar, "The Alzheimer's disease β-secretase enzyme, BACE1," *Springer Nature,* 2007.

[7] G. Verdile, S. Fuller, C. S. Atwood, S. M. Laws, S. E. Gandy and R. N. Martins, "The role of beta amyloid in Alzheimer's disease: still a cause of everything or the only one who got caught?," *Pharmacological Research,* vol. 50, no. 4, pp. 397-409, 2004.

[8] C. L.-D. U. Z. J. R. P.-P. Steffen Roßner, "Alzheimer's disease β-secretase BACE1 is not a neuron-specific enzyme," *journal of neurochemistry,* vol. 92, no. 2 , pp. 226-334, 2004.

[9] K. A, "The beta-amyloid cascade hypothesis: a sequence of events leading to neurodegeneration in Alzheimer's disease," *Neurologia i Neurochirurgia Polska,* pp. 405-411, 2004.

[10] D. M. Walsh and D. B. Teplow, "Chapter 4 - Alzheimer's Disease and the Amyloid β-Protein," in *Progress in Molecular Biology and Translational Science,*, 2012, p. 107.

[11] M.Sathya, P. Premkumar and C. Karthick, "BACE1 in Alzheimer's disease," *Clinica Chimica Acta,* vol. 414, pp. 171-178, 2012.

[12] E. L.D and S. C, "Disrupting β-Amyloid Aggregation for Alzheimer Disease Treatment," *Current Topics in Medicinal Chemistry,* vol. 7, pp. 115-126, 2007.

[13] J. C. T. D. K. W. S. C. G. E. Cheng-Ying Ho, "Beta-Amyloid, Phospho-Tau and Alpha-Synuclein Deposits Similar to Those in the Brain Are Not Identified in the Eyes of Alzheimer's and Parkinson's Disease Patients," *Brain Pathology,* vol. 24, no. 1, pp. 25-32, 2013.

[14] N. V, "ORIGIN AND DEVELOPMENT OF AYURVEDA: (A BRIEF HISTORY)," *Anc Sci Life,* pp. 1-7, 1981.

[15] L.-c. Mishra, B. B. Singh and S. Dagenais, "Ayurveda: A historical perspective and principles of the traditional healthcare system in India," *Alternative Therapies in Health and Medicine;,* p. 7, Mar 2001.

[16] L. L. W. Yogini S. Jaiswal, "A glimpse of Ayurveda – The forgotten history and principles of Indian traditional medicine," *Journal of Traditional and Complementary Medicine,* vol. 7, no. 1, pp. 50-53, Feb 2016.

[17] A. A. S. D. B. S. D. I. L. Michelle D. Nemetchek, "The Ayurvedic plant Bacopa monnieri inhibits inflammatory pathways in the brain," *Journal of Ethnopharmacology,* vol. 197, pp. 92-100, Feb 2017.

[18] S. C. Tushar Dubey, "Brahmi (Bacopa monnieri): An ayurvedic herb against the Alzheimer's disease," *Archives of Biochemistry and Biophysics,* vol. 676, p. 108153, November 2019.

[19] A. Russo and F. Borrelli, "Bacopa monniera, a reputed nootropic plant: an overview," *Phytomedicine,* vol. 12, no. 4, pp. 305-317, April 2005.

[20] U. A. S. G. D. R. P. R. G. D. D. V. T. A. D. Samarpita Banerjee, "Bacosides from Bacopa monnieri extract: An overview of the effects on neurological disorders," *Phytotherapy Research,* vol. 35, no. 10, pp. 5668-5679, July 2021.

[21] D. B. M. S. B. G. A. P. G. C. M. G. &. J. S. G. Steven Roodenrys Ph.D, "Chronic Effects of Brahmi (Bacopa monnieri) on Human Memory," *Neuropsychopharmacology,* pp. 279-281, November 2001.

[22] A. S. N. K. V. T. M. T. Shishir Goswami, "Effect of Bacopa monnieri on Cognitive functions in Alzheimer's," *International Journal of Collaborative Research on Internal Medicine & Public Health,* vol. 3, no. 4, p. 10, April 2011.

[23] K. S. Chaudhari, N. R. Tiwari, R. R. Tiwari and R. S. Sharma, "REVIEW ARTICLES| MAY 12 2017," *Annals of Neurosciences,* vol. 27, no. 2, May 2017.

[24] J. W. Z. F. G. G. T. B. H. W. I. S. P. B. H.M. Berman, "The Protein Data Bank," *Nucleic Acids Research,* vol. 28, no. 1, pp. 235-242, Jan 2000.

[25] M. M. W. M. D. S. T. J. M. Laskowski R A, "PROCHECK - a program to check the stereochemical quality of protein structures," pp. 283-291., 1993.

[26] C. J. C. T. e. a. Kim S, " PubChem 2023 update," *Nucleic Acids Res,* p. 373–380, 2003.

[27] B. M. J. C. M. C. V. T. O'Boyle NM, "Open Babel: An open chemical toolbox," *J Cheminform,* pp. 3-33, 2011.

[28] R. Vassar, "β-Secretase (BACE) as a drug target for alzheimer’s disease," *Science direct,* vol. 54, no. 12, pp. 1589-1602, 2002.

[29] T. Wisniewski, G. Ghiso and B. Frangione, "Biology of Aβ Amyloid in Alzheimer's Disease," *Neurobiology of Disease,* vol. 4, no. 5, pp. 313-328, 1997.